TD Cowen lowered the firm’s price target on NeoGenomics (NEO) to $12 from $17 and keeps a Buy rating on the shares. The firm had a sales miss and after also having a Q4 sales miss, its reiterated 2025 guidance appears aggressive.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO: